Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species.

Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species.

Item

http://www.wikidata.org/entity/Q34663202

Q34663202

about

Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977 HCV Kinetic Models and Their Implications in Drug Development Drug-drug interactions during antiviral therapy for chronic hepatitis C Chutes and ladders in hepatitis C nucleoside drug development The Mechanism of Action of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine Involves a Second Metabolic Pathway Leading to -D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine 5'-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479 Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication Visualization and measurement of ATP levels in living cells replicating hepatitis C virus genome RNA.Direct-acting antiviral agents for hepatitis C virus infection.Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase.Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex.Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection.Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites?Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends.Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs.Highlights in antiviral drug research: antivirals at the horizon.Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV Infection Evaluation of Sofosbuvir (β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine) as an inhibitor of Dengue virus replication.Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir Evaluation of the effect of mericitabine at projected therapeutic and supratherapeutic doses on cardiac repolarization in healthy subjects: A thorough QT/QTc study.PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups.Current and future use of nucleo(s)tide prodrugs in the treatment of hepatitis C virus infection.Emerging antiviral drugs

P2860

Q24621496-8B0BF699-57BC-4726-B1B6-2C358DC813A4 Q26801602-DC738E45-6E9E-4526-8B74-C22934C2BF1C Q26864887-F2B1BB13-766B-498D-BD8D-CDA4120CE931 Q26998630-1DA474C5-68D3-4DC3-85B5-8856A6B6049D Q27485329-DD7E4B20-C101-4140-8F8C-85BA8D4F4081 Q27487389-570C70B3-7691-46D9-86A3-18D5E4BB071B Q28476610-4F33B4FA-B8B1-4FEF-BAF7-66A43699E231 Q28485227-94FA49D4-6FCD-4D36-9906-7340B12C6316 Q28541682-8BD62587-02D5-47F5-8267-1EB7715B819C Q33798503-2E4C8866-11E0-452F-986D-B07A57288383 Q34045444-3B0050ED-B0F0-4908-B06A-F31838797543 Q34186975-96ECDC3B-5A44-4528-B5CE-793C1F4C4250 Q34321440-5CEE00E3-3141-4C52-9249-50C15B8EC59A Q34571043-7CDE5608-D036-4E5A-88F2-F1F401A39CC9 Q35139538-E6EC4EAD-EA6A-41CA-BDB8-C0A1F766FA16 Q35260330-BAE0E41F-90AC-4435-BDDB-E62433361CC3 Q35735135-9745514A-E1E2-452C-B5D2-E4E35B1FC24A Q35878898-B9B0193C-E728-4249-8E80-120576247433 Q37481292-30B9008C-5E92-4F90-A7EB-C9119AAC1A05 Q37701947-5959B4ED-E5B1-48C9-A02A-A7ADD45773A8 Q37855863-2B66E319-A709-48C2-BBDC-290BCC2271AF Q37998132-E22E8157-98BB-48B7-B4C4-20FCA6F9A6E3 Q38007145-EDDDBD27-4E90-4F9F-A66D-E76A526991D1 Q38848491-5114C24D-6A24-4A04-8E46-18DE8B5B4C48 Q39792685-C85141EE-C83B-47D2-A157-AA55FD33F511 Q40046618-61764039-10D7-47CD-A8F6-139EB04733FE Q41570509-A422F65A-D62E-420E-9F35-C53746EC5F1B Q41595435-1E437DF8-8B12-4595-9A18-80D6D112DA60 Q42221569-A7AE560F-A5C2-4EE7-BA32-DBD77CB47C99 Q42988582-52B98D39-967B-41C2-92FA-438B342F83E6 Q42988733-DC7EFB82-0483-4ADB-96D2-1718FC997ABC Q43042024-94EA92D0-EEA0-4407-92BE-1A998C2F67BA Q49797854-F6D44686-79A6-4106-A864-305E096550EC Q56786308-4405402A-AAC7-4CFF-BF97-45B8DB5B4B44

P2860

Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species.

Item

http://www.wikidata.org/entity/Q34663202

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

Characterization of the metabo ...... ctive 5'-triphosphate species.

@ast

Characterization of the metabo ...... ctive 5'-triphosphate species.

@en

Characterization of the metabo ...... -2'-fluoro-2'-C-methylcytidine

@nl

type

Item

label

Characterization of the metabo ...... ctive 5'-triphosphate species.

@ast

Characterization of the metabo ...... ctive 5'-triphosphate species.

@en

Characterization of the metabo ...... -2'-fluoro-2'-C-methylcytidine

@nl

prefLabel

Characterization of the metabo ...... ctive 5'-triphosphate species.

@ast

Characterization of the metabo ...... ctive 5'-triphosphate species.

@en

Characterization of the metabo ...... -2'-fluoro-2'-C-methylcytidine

@nl

P1476

Characterization of the metabo ...... ctive 5'-triphosphate species.

@en

P2093

David B Smith

http://www.w3.org/2001/XMLSchema#string

Han Ma

http://www.w3.org/2001/XMLSchema#string

Julian Symons

http://www.w3.org/2001/XMLSchema#string

Klaus Klumpp

http://www.w3.org/2001/XMLSchema#string

Mohammad Masjedizadeh

http://www.w3.org/2001/XMLSchema#string

Nick Cammack

http://www.w3.org/2001/XMLSchema#string

Nicole Robledo

http://www.w3.org/2001/XMLSchema#string

Samir Ali

http://www.w3.org/2001/XMLSchema#string

Teresa Lara-Jaime

http://www.w3.org/2001/XMLSchema#string

Vincent Leveque

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibitory Effect of 2'-Substituted Nucleosides on Hepatitis C Virus Replication Correlates with Metabolic Properties in Replicon Cells

Hepatitis C Virus RNA Synthesis in a Cell-Free System Isolated from Replicon-Containing Hepatoma Cells

Mechanism of Activation of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication.

Nucleoside and nucleotide inhibitors of HIV-1 replication.

P304

29812-29820

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M705274200

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

282

http://www.w3.org/2001/XMLSchema#string

P577

2007-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6140494

http://www.w3.org/2001/XMLSchema#string

P698

17698842

http://www.w3.org/2001/XMLSchema#string

Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species.

about

P2860

P2860

Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698